GDTC Stock — CytoMed Therapeutics Limited Ordinary Shares

CytoMed Therapeutics Limited Ordinary Shares (GDTC)

Updated October 16, 2026.

GDTC is a Stock. Total return is -78.0% over the past 3.5 years, 170.8 points behind SPY at 92.8%.

CytoMed Therapeutics Limited is a clinical-stage biopharmaceutical company developing cell-based immunotherapies for cancer and degenerative diseases, with its lead program being CTM-N2D, a chimeric antigen receptor therapy in Phase I trials, alongside several other cell therapy candidates in development across Singapore and Malaysia. The company does not currently have an established distribution schedule. This security appeals to investors with high risk tolerance seeking exposure to early-stage biotechnology development.

GDTC performance versus SPY

Price and return data through 2026-10-16.

Total return is -78.0% over the past 3.5 years, 170.8 points behind SPY at 92.8%. Over the past year its total return — price change plus distributions reinvested — is -60.9%. Its deepest 1-year drawdown was 73.1%.

GDTC key facts

Asset type

Stock

Asset class

Equity

Inception date

04/13/2023

Distribution frequency

None

Last close

$0.88 (as of 2026-10-16)

Market cap

$10,501,526

Average volume

7258.0

Beta

0.071

Payout ratio

0.0%

EPS

$-0.23

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

GDTC risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 73.1%.

Who may consider GDTC — and who may not

It is a weaker fit for investors who need monthly cash flow (GDTC does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on GDTC

• All tickers starting with G

Tagged: Healthcare.

Frequently asked questions